Multiple studies have indicated that circular RNAs (circRNAs) are closely associated with malignant tumor development and metastasis. However, the significance of circRNAs in primary hepatic carcinoma (PHC), particularly in the plasma, remains largely undetermined. In the current study, circRNA expression profiles in three pairs of tumor and adjacent normal samples from patients with PHC, were examined using circRNA chip screening. A total of 80 circRNAs were upregulated, while 75 circRNAs were downregulated in PHC tissues, relative to para-tumor tissues (fold change, ≥1.5). A total of two upregulated circRNAs and three downregulated circRNAs were selected as candidates for further validation of their differential expression. This was performed using reverse transcription-quantitative PCR with 11 pairs of PHC tissues and para-tumor tissues. The results indicated that hsa_circ_0003056 exhibited reduced expression in PHC tissues. Moreover, hsa_circ_0003056 and hsa_circ_0067127 were quantified in the plasma samples of 35 PHC patients and 32 healthy donors. The results revealed that hsa_circ_0067127 was significantly downregulated in the patients' plasma. Finally, a competing endogenous RNA network was constructed, which consisted of one circRNA (hsa_circ_0003056 or has_circ_0067127), five miRNAs and miRNA-targeted genes (mRNAs). Kyoto Encyclopedia of Genes and Genomes pathway analysis indicated that differentially expressed (DE) genes were significantly enriched in the pathway associated with 'regulation of the pluripotency of stem cells' for hsa_circ_0003056, and 'ubiquitin-mediated proteolysis' and 'prostate cancer' for hsa_circ_0067127. Gene ontology analysis revealed that DE genes were primarily associated with the 'modulation of kinase activity' and 'intracellular and transmembrane-ephrin receptor activity' for hsa_circ_0003056, 'artery morphogenesis activity', 'HOPS complex and transferase activity' and in 'transferring acyl groups' for hsa_circ_0067127. This approach indicated that hsa_circ_0003056 in PHC tissue, and hsa_circ_0067127 in PHC plasma, are downregulated and may be implicated in the tumorigenesis of PHC.
Introduction
Primary hepatic carcinoma (PHC) is one of the most common malignancies in China (1) . An estimated 466,000 new PHC cases, and 422,000 PHC-associated mortalities occurred in China in 2015, with only 10% of patients surviving >5 years (2) . Furthermore, due to the lack of sensitive markers for early diagnosis, only 10-20% of patients with PHC are suitable for surgical resection, local ablation and other potential therapies (3) . The current biomarkers that are used for the auxiliary diagnosis of PHC include alpha fetoprotein (AFP), AFP-L3 isoform ratio, glypican-3, des-γ-carboxy-prothrombin, golgi protein 73 and alpha L-fucus glycosidase. However, these markers, even when utilized together, are not sufficient for the identification or early diagnosis of PHC. It is therefore necessary to identify novel early diagnostic markers and therapeutic targets for use in liver cancer diagnosis and treatment (4) .
Abnormal tumor-suppressor gene inactivation or oncogene activation are leading causes of liver cancer, and a growing number of studies have indicated that circular RNAs (circRNAs)
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are associated with a variety of cellular activities (5) . circRNAs are a large class of endogenous, non-coding RNAs that feature covalently closed continuous loops with highly conserved sequences; they have been revealed to serve an important role in the regulation of gene expression during and after transcription (6) . The majority of circRNAs derive from exons, localize in the cytoplasm, and exhibit tissue/developmental stage-specific expression (7) . circRNAs can be detected in human blood samples and exhibit higher expression levels than corresponding linear mRNAs (8) . As previously reported, circRNAs have been demonstrated to serve a role in the occurrence and progression of a variety of tumor types, including esophageal squamous cell and basal cell carcinoma, as well as colon, ovarian and breast cancers (9) (10) (11) (12) (13) . These studies clearly demonstrate the potential use of circRNAs as tumor biomarkers (14) (15) (16) . It has recently been reported that hsa_circ_0001649, hsa_circ_0005075, hsa_ circ_0000130, hsa_circ_0004018 and hsa_circ_0001445 may represent potential biomarkers for hepatocellular carcinoma (HCC), and potentially influence PHC tumor occurrence and metastasis (17) (18) (19) (20) (21) . circRNAs act as a sponge for microRNAs (miRNAs), regulating downstream mRNA genes through a competing endogenous RNA (ceRNA) network (22) . Compared with miRNAs and long non-coding RNAs, circRNAs have not been extensively researched in HCC, with only a few studies focusing on their differential expression in liver cancer tissues. However, to the best of our knowledge, their expression in plasma has not yet been determined, and the use of ceRNA networks and their potential application in clinical diagnosis are yet to be elucidated.
In the present study, comprehensive circRNA expression profiles were analyzed in PHC tissues and paired adjacent normal tissues using circRNA chip screening. Differentially expressed (DE) circRNAs were further validated in PHC tissues and plasma samples using reverse transcription-quantitative (RT-q) PCR. Significant downregulation of hsa_circ_0003056 in PHC tissues and hsa_circ_0067127 in plasma was demonstrated. The ceRNA networks of hsa_circ_0003056 and hsa_circ_0067127 were constructed and analyzed using gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses.
Materials and methods
Patients and specimens. A total of 14 PHC tissue specimens and paired adjacent normal tissues, along with fresh plasma samples from 35 PHC patients and 32 healthy donors, were obtained between October 2016 and August 2018 at The Second Hospital of Nanjing (Nanjing, China). Non-tumorous tissues were removed 2.0 cm from the tumor edge and no obvious malignant cells were identified by a pathologist. Following dissection, all tissues were preserved in RNA storage solution (Shanghai SangonBiotech Co., Ltd.) and stored at -80˚C until further use. All tissues were confirmed by pathological examination and none of the patients received neoadjuvant therapy. The baseline characteristics and clinicopathological features of each patient were collected from the hospital digital health care system, and are summarized in Table I . The research procedures of the present study were approved by the Ethics Committee of the Second Hospital of Nanjing, and written informed consent was obtained from all enrolled participants.
circRNA expression profiles. A circRNA chip (Arraystar Human circRNAs Array V2; Zhejiang Kangchen Biotech Co., Ltd.) containing 13,617 probes specific to human circRNA splicing sites was used. A total of three pairs of tumor tissues and paired non-tumorous tissues from patients with PHC were analyzed using the circRNA chips, according to the manufacturer's protocol. The chips were then scanned using the Agilent Scanner G2505C (Agilent Technologies, Inc.), and the raw data were extracted using Agilent Feature Extraction software (version 11.5.1.1; Agilent Technologies, Inc.). Quantile normalization of the raw data and subsequent data processing were performed using the R software limma package 3.40.6 (http://www.bioconductor. org/packages/release/bioc/html/limma.html). Subsequently, low intensity filtering was performed, and circRNAs that appeared in ≥3 out of 6 samples, and had flags in 'P' or 'M' ('All Targets Value') were selected for further analyses. circRNAs that exhibited fold changes ≥1.5 and P≤0.05 were selected as the significant DE circRNAs. circRNA/miRNA interactions were predicted using Arraystar's home-made miRNA target prediction software, which was derived by modifying an existing software package from TargetScan (23) (http://www.targetscan.org/) and miRanda (24) (http://www. microrna. org/microrna/home.do). The miRNA support vector regression scores were identified and used to construct a 'Top 5' circRNA-miRNA-mRNA network for DE circRNAs.
Total RNA extraction and RT-qPCR. Total RNA was isolated from tumor tissues, adjacent normal tissues and plasma samples using the AllPure Tissue kit, HiPure Blood/Liquid RNA kit (Magen; http://www.magentec.com.cn/) and miRNeasy Serum/Plasma kit (Qiagen, GmbH) according to the manufacturers' protocols. The total RNA was quantified using a Colibri spectrometer (Titertek Berthold), and RNA integrity was assessed using electrophoresis on a denaturing agarose gel. Isolated RNA samples were stored at -80˚C prior to use. Total RNA from tissue (1.0 µg) or plasma (0.3 µg) was reverse transcribed into first-strand cDNA using the HiScript Q RT SuperMix for qPCR (+gDNA wiper; Vazyme) according to the manufacturer's protocol. qPCR was performed using the SYBR ® Green Master Mix (High ROX Premixed; Vazyme), with the Applied Biosystems™ QuantStudiot™ 3 Real-Time PCR system (Thermo Fisher Scientific, Inc.). circRNAs were analyzed with β-actin as the internal standard. The reactions were prepared as follows: 10 µl qPCR SYBR ® Green Master Mix (High Rox Premixed), 0.4 µl forward primer (10 µM), 0.4 µl reverse primer (10 µM), 8.2 µl RNase free water and 1 µl cDNA. The thermocycling conditions were as follows: 95˚C for 5 min, followed by 40 cycles of 95˚C for 10 sec and 60˚C for 30 sec, and a final step of 95˚C for 15 sec, 60˚C for 60 sec and 95˚C for 15 sec. All primers used in the present study were designed and synthesized by Geneseed Biotech Co., Ltd. and are listed in Table II .
Functional enrichment analyses and ceRNA network construction. GO term enrichment analysis (http://www. geneontology.org) covers three domains: Biological process (BP), cellular component (CC) and molecular function (MF). KEGG pathway enrichment analyses were conducted using the Database for Annotation, Visualization and Integrated Discovery 6.8 (25) , and the P-value (EASE-score, Fisher-P-value or Hypergeometric-P-value) denotes the significance of the pathway when correlated with the conditions. miRNAs that target circRNAs were predicted by surveying for 7-mer or 8-mer complementarity to seed region and the 3' pairing of each miRNA using TargetScan. For humans and mice, two databases were used to predict the target genes of miRNAs: TargetScan 7.1 (http://www.tatgetscan. org/vert_71/) and mirdb V5 (http://mirdb.org/miRDB). The overlapping results of the two databases for humans and mice were accepted. The miRNA-target interactions were then experimentally validated using the database miraTarbase 7.0 (http://mirtarbase.mbc.nctu.edu.tw/php/index.php). 
Hsa_circ_0003056
Hsa_circ_0067127 HBsAg, hepatitis B virus surface antigen; AFP, alpha fetal protein; SD, standard deviation; TNM, stage is a classification of malignant tumors; T, size or direct extent of the primary tumor; N, degree of spread to regional lymph nodes; M, presence of distant metastasis. 
Results
Identification of DE circRNAs in PHC tissues using circRNA chip screening. The expression patterns of circRNAs were determined using circRNA chip screening in three pairs of PHC tissues and adjacent non-tumorous tissues. Following microarray scanning and normalization, significant changes were observed. A total of 155 circRNAs were indicated to be DE in PHC tissues (80 upregulated and 75 downregulated), compared with the paired non-tumorous tissues (Table III) . A differential gene expression hierarchical cluster heat map of circRNA expression patterns clearly distinguished PHC tissues from paired adjacent normal tissues ( Fig. 1A ). In the volcano plot, green and red dots indicate the down-and upregulation of circRNAs expression in PHC tissues, respectively ( Fig. 1B) .
Confirmation of DE circRNAs in PHC tissues using RT-qPCR.
To confirm the differential expression of circRNAs (indicated by circRNA microarray screening), RT-qPCR was performed to assess the expression levels of five candidate DE circRNAs in PHC tissues, compared with adjacent normal tissues, derived from an additional 11 patients with PHC. The five circRNAs (two upregulated and three downregulated) were selected according to the following criteria: i) Fold-change >1.5; ii) P<0.05; iii) exonic-related circRNAs; iv) raw intensity ≥100; v) included in circBase; and vi) exhibiting a gene symbol or miRNA binding sites that were considered to be significantly associated with tumor occurrence. Only circRNAs that exhibited a ≥1.5-fold expression level difference were considered to display statistically significant changes (P<0.05). Moreover, complete and accurate sequence information, and other information regarding the selected exonic-related circRNAs, were retrieved from circBase. A group raw intensity of ≥100 ensured the reliability of the detected fluorescence values of circRNAs determined using the microassay. Finally, circRNAs may influence PHC development and progression through circRNA-miRNA-mRNA networks. Thus, only circRNAs whose target genes or miRNA binding sites had a predetermined association with cancer progression were preferentially selected. As exhibited in Fig. 2A , only hsa_circ_0003056 expression was consistently and significantly lower in PHC tissues when compared with paired adjacent non-tumorous tissues. The other three circRNAs exhibited a fold-change in expression level between 1.5 and 2, which was not significantly different from the adjacent tissues.
Expression levels and association with clinicopathological parameters of hsa_circ_0003056 and hsa_circ_0067127 in PHC patient plasma. Hsa_circ_0003056 expression levels were decreased in PHC tissues compared with paired, adjacent non-tumor tissues. Hsa_circ_0067127 also exhibited decreased expression levels in PHC tissues, but the difference was not significant compared with the adjacent non-tumorous tissues, which may be due to the small sample size. To determine whether changes in expression level were also reflected in patients' plasma, fresh plasma samples were collected from an additional 35 patients with PHC, and 32 healthy donors. Subsequently, the expression levels of hsa_circ_0003056 and hsa_circ_0067127 were detected using RT-qPCR. As indicated in Fig. 2B , no significant downregulation or upregulation of hsa_circ_0003056 was identified in the patients' plasma, when compared with healthy donor plasma. However, hsa_circ_0067127 was significantly downregulated in the PHC plasma. Stratified analyses of hsa_circ_0003056 and hsa_circ_0067127 levels in the plasma samples of patients with PHC was performed, and is summarized in Table I . Significant downregulation of hsa_circ_0003056 was observed in patients who were >60 years old compared those <60 years old. hsa_circ_0067127 levels were also significantly higher in patients with an AFP level <200 ng/ml. No association was demonstrated between other clinical and laboratory characteristics (including sex and HBsAg level) and hsa_circ_0003056.
Follow-up was carried out for the 35 patients with PHC and the median overall survival (OS) time was 69 months. Survival data were analyzed using the log-rank test and survival curves were generated using the Kaplan-Meier method. Regarding hsa_circ_0003056 expression, the corresponding 35 patients with PHC were separated into an hsa_circ_0003056 low-expression group (<mean value in healthy donors' plasma; n=15; OS=69) and hsa_circ_0003056 high-expression group (>mean value in healthy donors' plasma; n=20; OS=72). The difference between OS times observed between groups was not statistically significant (data not shown). In terms of hsa_circ_0067127 expression, only 3 out of 35 patients with PHC displayed higher expression in their plasma than the mean value in the healthy donors. As a result, the survival curves could not be analyzed.
Construction of ceRNA networks of hsa_circ_0003056 and hsa_circ_0067127, and KEGG/GO enrichment analyses. The target miRNAs of hsa_circ_0003056 and hsa_circ_0067127 were identified and ranked based on their mirSVR scores and TargetScan. This indicated that hsa_circ_0003056 and hsa_circ_0067127 serve as miRNA sponges, regulating the ceRNA network. The five top miRNAs were selected to establish circRNA-miRNA-mRNA networks: hsa-miR-211-5p, hsa-m iR-204 -5p, hsa-m iR-9-3p, hsa-m iR-2113 and hsa-miR-499a-5p targeting to hsa_circ_0003056 (Fig. 3A) , and hsa-miR-141-5p, hsa-miR-486-5p, hsa-miR-186-3p, h sa-m i R-6 47 a nd h sa -m i R-212 -5p t a rget i ng t o hsa_circ_0067127 (Fig. 3B) . Regarding hsa_circ_0003056, a Venn diagram (Fig. 4A ) indicated that overlapping results common to the two databases were accepted. TargetScan 7.1 and mirdbV5 are used to forecast the target genes of miRNAs. The bar plot presents the enrichment scores [-log 10 (P-value)] of the top 10 significant enrichment pathways. KEGG pathway analysis demonstrated that DE genes were significantly enriched in pathways regulating the pluripotency of stem cells (Fig. 4B) . The bar plot presents the enrichment score [-log10 (P-value)] values of the top 10 significant GO enrichments. The hsa_circ_0003056-miRNAs-targets network exhibited a strong Fig. 4C) . The overlapping results between the two databases were also accepted for hsa_circ_0067127 ( Fig. 4D) . DE genes were significantly enriched in the pathways associated with 'ubiquitin-mediated proteolysis' and 'prostate cancer' (Fig. 4E) . The top 10 significant GO enrichments are presented in Fig. 4F . The hsa_circ_0067127-miRNAs-targets network exhibited a strong association with 'artery morphogenesis activity', 'HOPS complex' and 'transferase activity, transferring acyl groups' in BP, CC and MF, respectively.
Cytoscape analysis of hsa_ circ_ 0003056-and hsa_ circ_0067127-miRNA-target gene interaction networks. Based on hsa_circ_0003056 and hsa_circ_0067127, the networks of five miRNAs with their target mRNAs were constructed. In these networks, green circular nodes represent mRNAs, pink diamond nodes represent miRNAs, gray lines represent those not experimentally validated, and blue lines represent those experimentally validated (miRTarBase 7.0.). Fig. 5 indicates the top five miRNAs targeting to hsa_circ_0003056 and their target mRNAs. The top three mRNAs corresponding to both hsa-miR-211-5p and hsa-miR-204-5p were adaptor related protein complex 1 subunit sigma 2, solute carrier family 37 Similarly, Fig. 6 presents the top five miRNAs targeting to hsa_circ_0067127 and their target mRNAs.
Discussion
It has been determined that circRNAs may influence the initiation and development of a range of different cancer types. Certain circRNAs are enriched in exosomes (16) , suggesting that they exhibit the potential to function as tumor biomarkers, and may therefore be used to support diagnosis. However, few reports have investigated this with regards to PHC tissues and plasma. The current study provided a comprehensive circRNA profile in three pairs of PHC tissues and adjacent tissues prior to treatment, using circRNA chip screening. A total of five circRNAs were selected for validation of their respective expression levels in both PHC tissues, and adjacent tissues from 11 patients, using RT-qPCR analysis. However, only hsa_circ_0003056 was confirmed to be significantly downregulated in PHC tissues. According to the initial analyses of circRNA chip screening, the gene coding for hsa_circ_0003056 is located on chromosome 22, and the sequence of its best transcript is NM_012399, with a gene symbol of phosphatidylinositol (Ptdins) transfer protein beta (PITPNB). The relatively linear PITPNB stimulates Ptdins-4-phosphate synthesis and signaling in eukaryotic cells (27) . However, whether PITPNB influences tumor progression is yet to be determined. Therefore, the current study analyzed the associations between circPITPNB and certain clinicopathological parameters. However, the results revealed no significant association, which may be due to the small sample size of 11 cases. Further functional experiments are required to determine the mechanism behind the downregulation of hsa_circ_0003056 expression in PHC tissues. Using RT-qPCR, hsa_circ_0003056 expression levels were determined in fresh plasma samples retrieved from 35 PHC patients and 32 healthy donors. The expression levels of hsa_circ_0003056 did not significantly decrease in the plasma taken from patients with PHC. This may be due to the fact that most of the plasma samples were collected from patients undergoing interventional therapy, and only a small number were subjected to specimen collection prior to treatment. It has been suggested that interventional therapies may influence the expression levels of hsa_circ_0003056 in the plasma. circRNAs are relatively stable in plasma, however, the total free nucleic acid content of the peripheral blood is low (28) . There are no stable, internal or precise quantification methods for the determination of these levels. β-actin or GAPDH can be used in plasma or serum (29) , but they are not ideal internal references due to their instability and high individual variation. Although circRNAs exhibit a degree of tissue specificity, they are expressed in plasma and can be detected. These circRNAs may represent novel potential serum biomarkers. For example, circRNA-284 and miR-221 both exhibit the potential to become diagnostic biomarkers of carotid plaque ruptures and strokes (30) . In the present study, the expression level of hsa_circ_0067127 was lower in PHC plasma but not in PHC tissue (compared to normal plasma and para-tumor tissues, respectively), and was also associated with AFP level, as determined by stratified analysis. To further validate the expression levels of hsa_circ_0003056 and hsa_circ_0067127 in PHC plasma, the plasmid vector method should be used in future studies as a standard to quantify the two circRNAs, with an increased sample size for improved reliability.
Mechanisms describing the roles of circRNAs in cancer progression have not been clearly elucidated. The primary function of circRNAs is to act as miRNA sponges by forming circRNA-miRNA-mRNA axes (22) . The circ_0067934/miR-1324/FZD5/b-catenin signaling complexes may serve as a promising therapeutic target for HCC intervention (31) . Other functions of circRNAs, such as their interaction with RNA-binding proteins and translating proteins, have previously been described (32) . In the present study, the top five target miRNAs that were indicated to interact with hsa_circ_0003056, were selected based on their mirSVR scores and TargetScan. These were hsa-miR-211-5p, hsa-m iR-204 -5p, hsa-m iR-9-3p, hsa-m iR-2113 and hsa-miR-499a-5p. Hsa-miR-211-5p levels in HCC tissues were lower than those in normal tissues, suggesting an inhibitory role in HCC by inhibiting zinc finger E-box-binding protein (ZEB2) expression (33) . Hsa-miR-211-5p is also associated with renal cell carcinoma, thyroid tumors and triple-negative breast cancer (34) (35) (36) . Hsa-miR-204-5p is associated with a variety of malignancies, including HCC and laryngeal squamous cell carcinoma (37, 38) . Whether hsa-miR-204-5p is associated with PHC progression, through its interaction with hsa_circ_0003056, remains undetermined. A practical method is urgently required to identify specific interactions between miRNAs and circRNAs, currently identified using complicated bioinformatics prediction networks. KEGG pathway analyses revealed that DE genes were significantly enriched in pathways that regulates the pluripotency of stem cells. GO analyses revealed that hsa_circ_0003056 was strongly associated with 'regulation of kinase activity', and 'intracellular and transmembrane-ephrin receptor activity' in BP, CC and MF, respectively, which is consistent with its linear form (PITPNB), a gene encoding a cytoplasmic protein that catalyzes the transfer of phosphatidylinositol and phosphatidylcholine between membranes.
In the future, functional experiments should be performed to further explore the mechanism of circRNA in the regulation of PHC progression. Hepatic carcinoma cell lines with high or low expression levels of hsa_circ_0003056 should be constructed, and used to conduct proliferation and migration experiments. The binding and co-localization of hsa_circ_0003056 with the top five target miRNAs should be confirmed, and the target genes (mRNAs) corresponding to the miRNAs (as shown using GO enrichment analyses) should be quantified.
In summary, hsa_circ_0003056 expression is significantly decreased in PHC tissues, but is relatively stable in plasma. Conversely, hsa_circ_0067127 is downregulated in PHC plasma but not in PHC tissue. The detailed molecular mechanisms by which hsa_circ_0003056 and hsa_circ_0067127 function as miRNA sponges to regulate PHC occurrence and development require further investigation.
